Literature DB >> 22094306

Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring.

Sander Croes1, Arjen H Koop, Stephan A van Gils, Cees Neef.   

Abstract

Therapeutic drug monitoring (TDM) of aminoglycosides has been a topic during the last thirty years. There is a tendency that - because of the once-daily regimen - TDM is considered not necessary anymore. Although once daily dosing has the potential for decreased toxicity, long-term usage can cause severe nephro- and ototoxicity. Furthermore, inadequate plasma concentrations can lead to treatment failure. This work is devoted to the development and application of the first mathematical model of aminoglycosides, which simulates in relation to the pharmacokinetics both their effects on bacteria as well as their nephrotoxicity and cochleotoxicity. Our software system is suitable for TDM. Based on theoretical considerations, a multi-compartment mathematical model in a numerical program in Matlab is derived that incorporates the antimicrobial effects of aminoglycosides, the saturable and active uptake into kidney cells, the reversible nephrotoxicity and the irreversible cochleotoxicity. Using fictitious person data, and an assumed pharmacokinetic and dynamic parameter set obtained from the literature, we simulated the drug concentrations, antibacterial effects, and toxicity over time in virtual patients to illustrate the benefits of optimized, efficacious dosage regimens that minimize (acceptable) nephro- and auditory ototoxicity. Our model confirms that extended-interval dosing seems the most appropriate to achieve this goal. By this manner, the present mathematical model contributes to an increase in our knowledge of how to obtain an optimized dosing strategy for individual patients. With the developed program, we are able to demonstrate that optimal aminoglycoside dosing still needs a sophisticated system of TDM.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094306     DOI: 10.1016/j.ejps.2011.10.022

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  8 in total

Review 1.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

2.  Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example.

Authors:  Tomas Radivoyevitch; Nopphon Siranart; Lynn Hlatky; Rainer Sachs
Journal:  AAPS J       Date:  2015-02-07       Impact factor: 4.009

3.  Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.

Authors:  Jürgen B Bulitta; Neang S Ly; Cornelia B Landersdorfer; Nicholin A Wanigaratne; Tony Velkov; Rajbharan Yadav; Antonio Oliver; Lisandra Martin; Beom Soo Shin; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

4.  Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy.

Authors:  Lana Nezic; Adrian Derungs; Marcel Bruggisser; Sarah Tschudin-Sutter; Stephan Krähenbühl; Manuel Haschke
Journal:  Eur J Clin Pharmacol       Date:  2014-04-23       Impact factor: 2.953

5.  Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients.

Authors:  Carolina Consuelo Llanos-Paez; Christine Staatz; Stefanie Hennig
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

6.  Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.

Authors:  Min Dong; Anna V Rodriguez; Chelsea A Blankenship; Gary McPhail; Alexander A Vinks; Lisa L Hunter
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

Review 7.  Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies).

Authors:  Carole Ichai; Christophe Vinsonneau; Bertrand Souweine; Fabien Armando; Emmanuel Canet; Christophe Clec'h; Jean-Michel Constantin; Michaël Darmon; Jacques Duranteau; Théophille Gaillot; Arnaud Garnier; Laurent Jacob; Olivier Joannes-Boyau; Laurent Juillard; Didier Journois; Alexandre Lautrette; Laurent Muller; Matthieu Legrand; Nicolas Lerolle; Thomas Rimmelé; Eric Rondeau; Fabienne Tamion; Yannick Walrave; Lionel Velly
Journal:  Ann Intensive Care       Date:  2016-05-27       Impact factor: 6.925

Review 8.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.